This document is an excerpt from the EUR-Lex website
Document E2025G00950
Medicinal products – List of marketing authorisations granted by the EEA EFTA States for the first half of 2024
Medicinal products – List of marketing authorisations granted by the EEA EFTA States for the first half of 2024
Medicinal products – List of marketing authorisations granted by the EEA EFTA States for the first half of 2024
OJ C, C/2025/950, 6.2.2025, ELI: http://data.europa.eu/eli/C/2025/950/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
Official Journal |
EN C series |
|
C/2025/950 |
6.2.2025 |
Medicinal products – List of marketing authorisations granted by the EEA EFTA States for the first half of 2024
(C/2025/950)
Subcommittee I on the free movement of goods
To be noted by the EEA Joint Committee
With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 January – 30 June 2024, at their meeting on 23 September 2024:
|
Annex I |
List of new marketing authorisations |
|
Annex II |
List of renewed marketing authorisations |
|
Annex III |
List of extended marketing authorisations |
|
Annex IV |
List of withdrawn marketing authorisations |
|
Annex V |
List of suspended marketing authorisations |
ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 1 January – 30 June 2024:
|
EU-Number |
Product |
Country |
Date of authorisation |
|
EU/1/24/1805 |
Agilus |
Iceland |
26.6.2024 |
|
EU/1/24/1805 |
Agilus |
Liechtenstein |
31.5.2024 |
|
EU/1/24/1805 |
Agilus |
Norway |
31.5.2024 |
|
EU/2/24/306 |
Alcort |
Liechtenstein |
30.4.2024 |
|
EU/2/24/306 |
Alcort |
Norway |
27.6.2024 |
|
EU/1/24/1824 |
ALTUVOCT |
Liechtenstein |
30.6.2024 |
|
EU/1/24/1824 |
ALTUVOCT |
Norway |
25.6.2024 |
|
EU/1/24/1796 |
Apremilast Accord |
Iceland |
3.6.2024 |
|
EU/1/24/1796 |
Apremilast Accord |
Liechtenstein |
30.4.2024 |
|
EU/1/24/1796 |
Apremilast Accord |
Norway |
16.5.2024 |
|
EU/1/24/1815 |
Awiqli |
Iceland |
27.6.2024 |
|
EU/1/24/1815 |
Awiqli |
Liechtenstein |
31.5.2024 |
|
EU/1/24/1815 |
Awiqli |
Norway |
22.5.2024 |
|
EU/1/23/1777 |
Azacitidine Kabi |
Iceland |
12.1.2024 |
|
EU/1/23/1777 |
Azacitidine Kabi |
Liechtenstein |
31.1.2024 |
|
EU/1/23/1777 |
Azacitidine Kabi |
Norway |
15.1.2024 |
|
EU/2/23/303 |
Bovilis Cryptium |
Iceland |
5.1.2024 |
|
EU/2/23/303 |
Bovilis Cryptium |
Norway |
23.1.2024 |
|
EU/1/23/1787 |
Casgevy |
Iceland |
22.2.2024 |
|
EU/1/23/1787 |
Casgevy |
Liechtenstein |
29.2.2024 |
|
EU/1/23/1787 |
Casgevy |
Norway |
19.2.2024 |
|
EU/1/24/1806 |
Celldemic |
Iceland |
21.5.2024 |
|
EU/1/24/1806 |
Celldemic |
Liechtenstein |
30.4.2024 |
|
EU/1/24/1806 |
Celldemic |
Norway |
22.5.2024 |
|
EU/1/23/1769 |
Dabigatran etexilate Leon Farma |
Iceland |
18.3.2024 |
|
EU/1/23/1769 |
Dabigatran etexilate Leon Farma |
Liechtenstein |
29.2.2024 |
|
EU/1/23/1769 |
Dabigatran etexilate Leon Farma |
Norway |
26.3.2024 |
|
EU/1/24/1811 |
Dimethyl fumarate Accord |
Iceland |
16.5.2024 |
|
EU/1/24/1811 |
Dimethyl fumarate Accord |
Liechtenstein |
30.4.2024 |
|
EU/1/24/1811 |
Dimethyl fumarate Accord |
Norway |
26.4.2024 |
|
EU/1/24/1814 |
Dimethyl fumarate Mylan |
Iceland |
16.5.2024 |
|
EU/1/24/1814 |
Dimethyl fumarate Mylan |
Liechtenstein |
30.4.2024 |
|
EU/1/24/1814 |
Dimethyl fumarate Mylan |
Norway |
26.4.2024 |
|
EU/1/24/1810 |
Dimethyl fumarate Neuraxpharm |
Iceland |
17.5.2024 |
|
EU/1/24/1810 |
Dimethyl fumarate Neuraxpharm |
Liechtenstein |
30.4.2024 |
|
EU/1/24/1810 |
Dimethyl fumarate Neuraxpharm |
Norway |
26.4.2024 |
|
EU/2/24/307 |
DIVENCE PENTA |
Liechtenstein |
30.4.2024 |
|
EU/2/24/307 |
DIVENCE PENTA |
Norway |
11.6.2024 |
|
EU/2/24/310 |
DIVENCE Tetra |
Liechtenstein |
31.5.2024 |
|
EU/2/24/310 |
DIVENCE Tetra |
Norway |
3.6.2024 |
|
EU/1/24/1808 |
Emblaveo |
Iceland |
29.5.2024 |
|
EU/1/24/1808 |
Emblaveo |
Liechtenstein |
30.4.2024 |
|
EU/1/24/1808 |
Emblaveo |
Norway |
7.5.2024 |
|
EU/1/24/1819 |
Eribulin Baxter |
Liechtenstein |
30.6.2024 |
|
EU/1/24/1794 |
EXBLIFEP |
Iceland |
5.4.2024 |
|
EU/1/24/1794 |
EXBLIFEP |
Liechtenstein |
31.3.2024 |
|
EU/1/24/1794 |
EXBLIFEP |
Norway |
26.3.2024 |
|
EU/1/24/1802 |
FABHALTA |
Iceland |
25.6.2024 |
|
EU/1/24/1802 |
FABHALTA |
Liechtenstein |
31.5.2024 |
|
EU/1/24/1802 |
FABHALTA |
Norway |
29.5.2024 |
|
EU/1/23/1788 |
Filspari |
Iceland |
14.5.2024 |
|
EU/1/23/1788 |
Filspari |
Liechtenstein |
30.4.2024 |
|
EU/1/23/1788 |
Filspari |
Norway |
16.5.2024 |
|
EU/1/24/1816 |
Fluenz |
Liechtenstein |
30.6.2024 |
|
EU/1/24/1816 |
Fluenz |
Norway |
6.6.2024 |
|
EU/1/24/1827 |
FRUZAQLA |
Liechtenstein |
30.6.2024 |
|
EU/1/24/1827 |
FRUZAQLA |
Norway |
27.6.2024 |
|
EU/1/23/1791 |
Ibuprofen Gen.Orph |
Iceland |
13.3.2024 |
|
EU/1/23/1791 |
Ibuprofen Gen.Orph |
Liechtenstein |
29.2.2024 |
|
EU/1/23/1791 |
Ibuprofen Gen.Orph |
Norway |
23.2.2024 |
|
EU/1/24/1807 |
Incellipan |
Iceland |
21.5.2024 |
|
EU/1/24/1807 |
Incellipan |
Liechtenstein |
30.4.2024 |
|
EU/1/24/1807 |
Incellipan |
Norway |
16.5.2024 |
|
EU/2/24/315 |
Innovax-ND-H5 |
Liechtenstein |
31.5.2024 |
|
EU/2/24/315 |
Innovax-ND-H5 |
Norway |
3.6.2024 |
|
EU/1/24/1828 |
IXCHIQ |
Liechtenstein |
30.6.2024 |
|
EU/1/24/1818 |
JERAYGO |
Liechtenstein |
30.6.2024 |
|
EU/1/24/1813 |
Jubbonti |
Iceland |
3.6.2024 |
|
EU/1/24/1813 |
Jubbonti |
Liechtenstein |
31.5.2024 |
|
EU/1/24/1813 |
Jubbonti |
Norway |
22.5.2024 |
|
EU/1/23/1744 |
Krazati |
Iceland |
12.1.2024 |
|
EU/1/23/1744 |
Krazati |
Liechtenstein |
31.1.2024 |
|
EU/1/23/1744 |
Krazati |
Norway |
15.1.2024 |
|
EU/2/24/308 |
Lexylan |
Liechtenstein |
30.4.2024 |
|
EU/2/24/308 |
Lexylan |
Norway |
15.5.2024 |
|
EU/2/24/311 |
Lotimax |
Liechtenstein |
30.4.2024 |
|
EU/2/24/311 |
Lotimax |
Norway |
15.5.2024 |
|
EU/1/24/1798 |
Lytenava |
Iceland |
25.6.2024 |
|
EU/1/24/1798 |
Lytenava |
Liechtenstein |
31.5.2024 |
|
EU/1/24/1798 |
Lytenava |
Norway |
30.5.2024 |
|
EU/1/23/1789 |
Mevlyq |
Iceland |
23.2.2024 |
|
EU/1/23/1789 |
Mevlyq |
Liechtenstein |
29.2.2024 |
|
EU/1/23/1789 |
Mevlyq |
Norway |
19.2.2024 |
|
EU/1/23/1778 |
Naveruclif |
Iceland |
12.1.2024 |
|
EU/1/23/1778 |
Naveruclif |
Liechtenstein |
31.1.2024 |
|
EU/1/23/1778 |
Naveruclif |
Norway |
10.1.2024 |
|
EU/1/24/1804 |
Neoatricon |
Iceland |
25.6.2024 |
|
EU/1/24/1804 |
Neoatricon |
Liechtenstein |
31.5.2024 |
|
EU/1/24/1804 |
Neoatricon |
Norway |
30.5.2024 |
|
EU/1/24/1795 |
Niapelf |
Iceland |
5.4.2024 |
|
EU/1/24/1795 |
Niapelf |
Liechtenstein |
31.3.2024 |
|
EU/1/24/1795 |
Niapelf |
Norway |
3.4.2024 |
|
EU/1/24/1803 |
Nintedanib Accord |
Iceland |
15.5.2024 |
|
EU/1/24/1803 |
Nintedanib Accord |
Liechtenstein |
30.4.2024 |
|
EU/1/24/1803 |
Nintedanib Accord |
Norway |
29.4.2024 |
|
EU/2/23/304 |
Nobivac LoVo L4 |
Norway |
11.3.2024 |
|
EU/2/24/309 |
Nobilis Multriva RT+IBm+ND+Gm+REOm+EDS |
Liechtenstein |
31.5.2024 |
|
EU/2/24/309 |
Nobilis Multriva RT+IBm+ND+Gm+REOm+EDS |
Norway |
15.5.2024 |
|
EU/1/24/1822 |
Obgemsa |
Liechtenstein |
30.6.2024 |
|
EU/1/23/1782 |
Omjjara |
Iceland |
21.2.2024 |
|
EU/1/23/1782 |
Omjjara |
Liechtenstein |
31.1.2024 |
|
EU/1/23/1782 |
Omjjara |
Norway |
29.1.2024 |
|
EU/1/24/1817 |
Omlyclo |
Iceland |
3.6.2024 |
|
EU/1/24/1817 |
Omlyclo |
Liechtenstein |
31.5.2024 |
|
EU/1/24/1817 |
Omlyclo |
Norway |
30.5.2024 |
|
EU/1/23/1785 |
Pomalidomide Viatris |
Iceland |
19.3.2024 |
|
EU/1/23/1785 |
Pomalidomide Viatris |
Liechtenstein |
29.2.2024 |
|
EU/1/23/1785 |
Pomalidomide Viatris |
Norway |
22.3.2024 |
|
EU/1/24/1801 |
Pyzchiva |
Iceland |
16.5.2024 |
|
EU/1/24/1801 |
Pyzchiva |
Liechtenstein |
30.4.2024 |
|
EU/1/24/1801 |
Pyzchiva |
Norway |
29.4.2024 |
|
EU/1/23/1783 |
Qalsody |
Iceland |
25.6.2024 |
|
EU/1/23/1783 |
Qalsody |
Liechtenstein |
31.05.2024 |
|
EU/1/23/1783 |
Qalsody |
Norway |
04.6.2024 |
|
EU/2/24/314 |
RESPIVAC TRT |
Liechtenstein |
31.5.2024 |
|
EU/2/24/314 |
RESPIVAC TRT |
Norway |
20.6.2024 |
|
EU/1/23/1779 |
Rimmyrah |
Iceland |
12.1.2024 |
|
EU/1/23/1779 |
Rimmyrah |
Liechtenstein |
31.1.2024 |
|
EU/1/23/1779 |
Rimmyrah |
Norway |
16.1.2024 |
|
EU/1/23/1780 |
Rystiggo |
Iceland |
10.1.2024 |
|
EU/1/23/1780 |
Rystiggo |
Liechtenstein |
31.1.2024 |
|
EU/1/23/1780 |
Rystiggo |
Norway |
10.1.2024 |
|
EU/1/24/1793 |
Ryzneuta |
Iceland |
5.4.2024 |
|
EU/1/24/1793 |
Ryzneuta |
Liechtenstein |
31.3.2024 |
|
EU/1/24/1793 |
Ryzneuta |
Norway |
26.3.2024 |
|
EU/1/23/1786 |
Skyclarys |
Iceland |
11.3.2024 |
|
EU/1/23/1786 |
Skyclarys |
Liechtenstein |
29.2.2024 |
|
EU/1/23/1786 |
Skyclarys |
Norway |
19.2.2024 |
|
EU/1/23/1781 |
Spexotras |
Iceland |
16.1.2024 |
|
EU/1/23/1781 |
Spexotras |
Liechtenstein |
31.1.2024 |
|
EU/1/23/1781 |
Spexotras |
Norway |
16.1.2024 |
|
EU/1/24/1797 |
Tizveni |
Iceland |
3.6.2024 |
|
EU/1/24/1797 |
Tizveni |
Liechtenstein |
30.4.2024 |
|
EU/1/24/1797 |
Tizveni |
Norway |
29.4.2024 |
|
EU/1/24/1825 |
Tofidence |
Liechtenstein |
30.6.2024 |
|
EU/2/24/312 |
Trilocur |
Liechtenstein |
31.5.2024 |
|
EU/2/24/312 |
Trilocur |
Norway |
15.5.2024 |
|
EU/2/24/313 |
Trilorale |
Liechtenstein |
31.5.2024 |
|
EU/2/24/313 |
Trilorale |
Norway |
15.5.2024 |
|
EU/1/24/1820 |
Truqap |
Liechtenstein |
30.6.2024 |
|
EU/1/24/1820 |
Truqap |
Norway |
24.6.2024 |
|
EU/1/23/1784 |
Uzpruvo |
Iceland |
10.1.2024 |
|
EU/1/23/1784 |
Uzpruvo |
Liechtenstein |
31.1.2024 |
|
EU/1/23/1784 |
Uzpruvo |
Norway |
11.1.2024 |
|
EU/1/23/1790 |
Velsipity |
Iceland |
13.3.2024 |
|
EU/1/23/1790 |
Velsipity |
Liechtenstein |
29.2.2024 |
|
EU/1/23/1790 |
Velsipity |
Norway |
21.2.2024 |
|
EU/1/24/1792 |
Voydeya |
Iceland |
17.5.2024 |
|
EU/1/24/1792 |
Voydeya |
Liechtenstein |
30.4.2024 |
|
EU/1/24/1792 |
Voydeya |
Norway |
29.4.2024 |
|
EU/1/24/1823 |
Wezenla |
Liechtenstein |
30.6.2024 |
|
EU/1/24/1812 |
Wyost |
Iceland |
25.6.2024 |
|
EU/1/24/1812 |
Wyost |
Liechtenstein |
31.5.2024 |
|
EU/1/24/1812 |
Wyost |
Norway |
27.5.2024 |
|
EU/1/24/1800 |
ZYNYZ |
Iceland |
15.5.2024 |
|
EU/1/24/1800 |
ZYNYZ |
Liechtenstein |
30.4.2024 |
|
EU/1/24/1800 |
ZYNYZ |
Norway |
29.4.2024 |
ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 January – 30 June 2024:
|
EU-Number |
Product |
Country |
Date of authorisation |
|
EU/1/21/1539 |
Abecma |
Liechtenstein |
31.3.2024 |
|
EU/1/21/1539 |
Abecma |
Norway |
4.4.2024 |
|
EU/1/18/1264 |
Alunbrig |
Norway |
17.1.2024 |
|
EU/1/19/1368 |
Ambrisentan Mylan |
Iceland |
9.4.2024 |
|
EU/1/19/1368 |
Ambrisentan Mylan |
Liechtenstein |
31.3.2024 |
|
EU/1/19/1368 |
Ambrisentan Mylan |
Norway |
3.4.2024 |
|
EU/2/19/239 |
Baycox Iron |
Liechtenstein |
31.3.2024 |
|
EU/2/19/239 |
Baycox Iron |
Norway |
4.4.2024 |
|
EU/1/20/1474 |
BLENREP |
Liechtenstein |
29.2.2024 |
|
EU/2/13/158 |
Bravecto |
Norway |
27.6.2024 |
|
EU/1/22/1648 |
CARVYKTI |
Iceland |
19.3.2024 |
|
EU/1/22/1648 |
CARVYKTI |
Liechtenstein |
31.3.2024 |
|
EU/1/22/1648 |
CARVYKTI |
Norway |
3.4.2024 |
|
EU/1/23/1742 |
Columvi |
Liechtenstein |
31.5.2024 |
|
EU/1/23/1742 |
Columvi |
Norway |
13.6.2024 |
|
EU/1/19/1365 |
Cufence |
Liechtenstein |
31.5.2024 |
|
EU/1/19/1365 |
Cufence |
Norway |
27.5.2024 |
|
EU/1/18/1349 |
Dectova |
Iceland |
16.1.2024 |
|
EU/1/18/1349 |
Dectova |
Liechtenstein |
31.1.2024 |
|
EU/1/18/1349 |
Dectova |
Norway |
16.1.2024 |
|
EU/1/13/875 |
Deltyba |
Iceland |
18.3.2024 |
|
EU/1/13/875 |
Deltyba |
Liechtenstein |
29.2.2024 |
|
EU/1/13/875 |
Deltyba |
Norway |
2.4.2024 |
|
EU/1/19/1373 |
Doptelet |
Iceland |
11.3.2024 |
|
EU/1/19/1373 |
Doptelet |
Liechtenstein |
29.2.2024 |
|
EU/1/19/1373 |
Doptelet |
Norway |
14.3.2024 |
|
EU/1/19/1370 |
Dovato |
Iceland |
11.4.2024 |
|
EU/1/19/1370 |
Dovato |
Liechtenstein |
31.3.2024 |
|
EU/1/19/1370 |
Dovato |
Norway |
3.4.2024 |
|
EU/1/19/1374 |
Esperoct |
Iceland |
23.2.2024 |
|
EU/1/19/1374 |
Esperoct |
Liechtenstein |
29.2.2024 |
|
EU/1/19/1374 |
Esperoct |
Norway |
16.2.2024 |
|
EU/2/18/233 |
Evant |
Norway |
4.1.2024 |
|
EU/1/18/1326 |
Flucelvax Tetra |
Iceland |
10.1.2024 |
|
EU/1/18/1326 |
Flucelvax Tetra |
Liechtenstein |
31.12.2023 (1) |
|
EU/1/18/1326 |
Flucelvax Tetra |
Norway |
11.1.2024 |
|
EU/2/19/240 |
Frontpro |
Norway |
19.2.2024 |
|
EU/1/18/1337 |
GHRYVELIN |
Iceland |
16.1.2024 |
|
EU/1/18/1337 |
GHRYVELIN |
Liechtenstein |
31.1.2024 |
|
EU/1/18/1337 |
GHRYVELIN |
Norway |
17.1.2024 |
|
EU/1/19/1384 |
Giapreza |
Liechtenstein |
31.5.2024 |
|
EU/1/19/1384 |
Giapreza |
Norway |
27.5.2024 |
|
EU/1/19/1375 |
Grasustek |
Liechtenstein |
31.5.2024 |
|
EU/1/19/1375 |
Grasustek |
Norway |
27.5.2024 |
|
EU/1/14/987 |
Holoclar |
Iceland |
18.3.2024 |
|
EU/1/14/987 |
Holoclar |
Liechtenstein |
24.2.2024 |
|
EU/1/14/987 |
Holoclar |
Norway |
6.3.2024 |
|
EU/1/19/1390 |
Inbrija |
Liechtenstein |
30.6.2024 |
|
EU/1/19/1390 |
Inbrija |
Norway |
25.6.2024 |
|
EU/1/21/1538 |
Jemperli |
Liechtenstein |
31.12.2023 (1) |
|
EU/1/21/1538 |
Jemperli |
Norway |
12.3.2024 |
|
EU/1/22/1657 |
Kinpeygo |
Liechtenstein |
30.6.2024 |
|
EU/1/21/1552 |
Koselugo |
Liechtenstein |
30.4.2024 |
|
EU/1/12/1552 |
Koselugo |
Norway |
7.5.2024 |
|
EU/1/19/1383 |
Lacosamide UCB |
Liechtenstein |
30.4.2024 |
|
EU/1/19/1383 |
Lacosamide UCB |
Norway |
10.4.2024 |
|
EU/1/19/1355 |
Lorviqua |
Iceland |
12.4.2024 |
|
EU/1/19/1355 |
Lorviqua |
Liechtenstein |
30.4.2024 |
|
EU/1/19/1355 |
Lorviqua |
Norway |
12.4.2024 |
|
EU/1/22/1649 |
Lunsumio |
Liechtenstein |
30.4.2024 |
|
EU/1/22/1649 |
Lunsumio |
Norway |
2.5.2024 |
|
EU/1/19/1381 |
LysaKare |
Liechtenstein |
30.4.2024 |
|
EU/1/19/1381 |
LysaKare |
Norway |
16.5.2024 |
|
EU/1/23/1741 |
Lytgobi |
Liechtenstein |
31.5.2024 |
|
EU/1/23/1741 |
Lytgobi |
Norway |
5.6.2024 |
|
EU/1/18/1348 |
Mulpleo |
Iceland |
16.1.2024 |
|
EU/1/18/1348 |
Mulpleo |
Liechtenstein |
31.1.2024 |
|
EU/1/18/1348 |
Mulpleo |
Norway |
10.1.2024 |
|
EU/1/15/1078 |
Natpar |
Iceland |
18.3.2024 |
|
EU/1/15/1078 |
Natpar |
Liechtenstein |
29.02.2024 |
|
EU/1/15/1078 |
Natpar |
Norway |
27.2.2024 |
|
EU/1/19/1364 |
NUCEIVA |
Liechtenstein |
31.5.2024 |
|
EU/1/19/1364 |
NUCEIVA |
Norway |
30.5.2024 |
|
EU/1/18/1345 |
Ondexxya |
Iceland |
11.4.2024 |
|
EU/1/18/1345 |
Ondexxya |
Liechtenstein |
31.3.2024 |
|
EU/1/18/1345 |
Ondexxya |
Norway |
8.4.2024 |
|
EU/1/19/1362 |
Palynziq |
Liechtenstein |
30.4.2024 |
|
EU/1/19/1362 |
Palynziq |
Norway |
16.5.2024 |
|
EU/1/16/1089 |
Pandemic influenza vaccine H5N1 AstraZeneca |
Liechtenstein |
30.4.2024 |
|
EU//16/1089 |
Pandemic influenza vaccine H5N1 AstraZeneca |
Norway |
7.5.2024 |
|
EU/1/18/1317 |
Pazenir |
Iceland |
10.1.2024 |
|
EU/1/18/1317 |
Pazenir |
Liechtenstein |
31.1.2024 |
|
EU/1/18/1317 |
Pazenir |
Norway |
10.1.2024 |
|
EU/1/21/1535 |
Pemazyre |
Iceland |
18.3.2024 |
|
EU/1/21/1535 |
Pemazyre |
Liechtenstein |
29.2.2024 |
|
EU/1/21/1535 |
Pemazyre |
Norway |
6.3.2024 |
|
EU/1/19/1379 |
Posaconazole Accord |
Liechtenstein |
30.4.2024 |
|
EU/1/19/1379 |
Posaconazole Accord |
Norway |
12.4.2024 |
|
EU/1/19/1380 |
Posaconazole AHCL |
Iceland |
17.4.2024 |
|
EU/1/19/1380 |
Posaconazole AHCL |
Liechtenstein |
30.4.2024 |
|
EU/1/19/1380 |
Posaconazole AHCL |
Norway |
16.4.2024 |
|
EU/2/19/237 |
ReproCyc ParvoFLEX |
Liechtenstein |
31.3.2024 |
|
EU/2/19/237 |
ReproCyc ParvoFLEX |
Norway |
4.4.2024 |
|
EU/1/20/1527 |
Retsevmo |
Iceland |
10.1.2024 |
|
EU/1/20/1527 |
Retsevmo |
Liechtenstein |
31.1.2024 |
|
EU/1/20/1527 |
Retsevmo |
Norway |
16.1.2024 |
|
EU/1/20/1460 |
Rozlytrek |
Liechtenstein |
31.5.2024 |
|
EU/1/20/1460 |
Rozlytrek |
Norway |
28.5.2024 |
|
EU/1/19/1369 |
Sixmo |
Iceland |
11.4.2024 |
|
EU/1/19/1369 |
Sixmo |
Liechtenstein |
31.3.2024 |
|
EU/1/19/1369 |
Sixmo |
Norway |
3.4.2024 |
|
EU/1/19/1361 |
Skyrizi |
Iceland |
16.1.2024 |
|
EU/1/19/1361 |
Skyrizi |
Liechtenstein |
31.1.2024 |
|
EU/1/19/1361 |
Skyrizi |
Norway |
16.1.2024 |
|
EU/2/19/248 |
Stelfonta |
Norway |
4.3.2024 |
|
EU/1/19/1372 |
Striascan |
Iceland |
20.3.2024 |
|
EU/1/19/1372 |
Striascan |
Liechtenstein |
31.3.2024 |
|
EU/1/19/1372 |
Striascan |
Norway |
26.3.2024 |
|
EU/1/23/1748 |
TALVEY |
Liechtenstein |
30.6.2024 |
|
EU/1/23/1748 |
TALVEY |
Norway |
25.6.2024 |
|
EU/1/19/1377 |
Talzenna |
Liechtenstein |
30.4.2024 |
|
EU/1/19/1377 |
Talzenna |
Norway |
22.4.2024 |
|
EU/1/20/1492 |
Tecartus |
Norway |
16.1.2024 |
|
EU/1/22/1675 |
TECVAYLI |
Liechtenstein |
30.6.2024 |
|
EU/1/22/1675 |
TECVAYLI |
Norway |
25.6.2024 |
|
EU/1/18/1351 |
Trecondi |
Iceland |
11.1.2024 |
|
EU/1/18/1351 |
Trecondi |
Liechtenstein |
31.1.2024 |
|
EU/1/18/1351 |
Trecondi |
Norway |
10.1.2024 |
|
EU/1/19/1371 |
Ultomiris |
Liechtenstein |
30.4.2024 |
|
EU/1/19/1371 |
Ultomris |
Norway |
5.6.2024 |
|
EU/2/14/168 |
Versican Plus Pi |
Liechtenstein |
30.6.2024 |
|
EU/2/14/168 |
Versican Plus Pi |
Norway |
25.6.2024 |
|
EU/1/19/1360 |
Waylivra |
Iceland |
20.3.2024 |
|
EU/1/19/1360 |
Waylivra |
Liechtenstein |
31.3.2024 |
|
EU/1/19/1360 |
Waylivra |
Norway |
3.4.2024 |
|
EU/1/19/1399 |
Xospata |
Liechtenstein |
30.6.2024 |
|
EU/1/19/1366 |
Xromi |
Liechtenstein |
31.5.2024 |
|
EU/1/19/1366 |
Xromi |
Norway |
16.5.2024 |
|
EU/1/14/938 |
Zydelig |
Liechtenstein |
30.6.2024 |
(1) Authorisation was unintentionally omitted from the list for the 2nd half of 2023.
ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 1 January – 30 June 2024:
|
EU-Number |
Product |
Country |
Date of authorisation |
|
EU/1/13/882/009-010 |
ABILIFY MAINTENA |
Iceland |
11.4.2024 |
|
EU/1/13/882/009-010 |
ABILIFY MAINTENA |
Norway |
30.4.2024 |
|
EU/1/16/1164/010-022 |
AMGEVITA |
Iceland |
27.6.2024 |
|
EU/1/16/1164/010-022 |
AMGEVITA |
Norway |
23.5.2024 |
|
EU/1/20/1528/025 |
Comirnaty |
Iceland |
28.6.2024 |
|
EU/1/20/1528/025-026 |
Comirnaty |
Norway |
28.5.2024 |
|
EU/1/12/797/003 |
Eylea |
Iceland |
10.1.2024 |
|
EU/1/12/797/003 |
Eylea |
Norway |
10.1.2024 |
|
EU/1/12/782/010-011 |
Kalydeco |
Iceland |
19.6.2024 |
|
EU/1/12/782/010-011 |
Kalydeco |
Norway |
30.4.2024 |
|
EU/1/21/1603/004 |
Lumykras |
Iceland |
28.6.2024 |
|
EU/1/21/1603/004 |
Lumykras |
Norway |
22.5.2024 |
|
EU/1/18/1315/003-004 |
Mektovi |
Norway |
17.6.2024 |
|
EU/1/22/1685/049-060 |
Mounjaro |
Iceland |
14.6.2024 |
|
EU/1/22/1685/049-060 |
Mounjaro |
Norway |
2.5.2024 |
|
EU/1/17/1231/003 |
Ocrevus |
Norway |
20.6.2024 |
|
EU/1/21/1251/012-013 |
Ozempic |
Norway |
17.6.2024 |
|
EU/1/19/1361/006 |
Skyrizi |
Iceland |
16.1.2024 |
|
EU/1/19/1377/007 |
Talzenna |
Iceland |
16.1.2024 |
|
EU/1/19/1377/007 |
Talzenna |
Norway |
11.1.2024 |
|
EU/1/17/1220/003 |
Tecentriq |
Iceland |
17.1.2024 |
|
EU/1/17/1220/003 |
Tecentriq |
Norway |
16.1.2024 |
|
EU/1/10/622/004 |
Tepadina |
Iceland |
8.4.2024 |
|
EU/1/10/622/004 |
Tepadina |
Norway |
3.4.2024 |
|
EU/1/22/1693/005-012 |
Teriflunomide Accord |
Iceland |
27.6.2024 |
|
EU/1/22/1693/005-012 |
Teriflunomide Accord |
Norway |
3.6.2024 |
|
EU/1/15/1083/012-013 |
Uptravi |
Iceland |
11.4.2024 |
|
EU/1/15/1083/012-013 |
Uptravi |
Norway |
5.4.2024 |
|
EU/1/17/1179/011 |
Veltassa |
Iceland |
10.1.2024 |
|
EU/1/17/1179/011 |
Veltassa |
Norway |
11.1.2024 |
|
EU/1/98/077/026-029 |
Viagra |
Iceland |
23.2.2024 |
|
EU/1/98/077/026-029 |
Viagra |
Norway |
19.2.2024 |
|
EU/1/21/1608/012 |
Wegovy |
Norway |
17.6.2024 |
ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 January – 30 June 2024:
|
EU-Number |
Product |
Country |
Date of withdrawal |
|
EU/2/10/118 |
Activyl |
Norway |
24.1.2024 |
|
EU/1/18/1292 |
Apealea |
Iceland |
23.2.2024 |
|
EU/1/18/1292 |
Apealea |
Liechtenstein |
29.2.2024 |
|
EU/1/18/1292 |
Apealea |
Norway |
22.2.2024 |
|
EU/1/20/1474 |
Blenrep |
Iceland |
16.4.2024 |
|
EU/1/20/1474 |
Blenrep |
Liechtenstein |
29.2.2024 |
|
EU/1/20/1474 |
Blenrep |
Norway |
28.2.2024 |
|
EU/2/17/218 |
Bovilis Blue-8 |
Iceland |
12.4.2024 |
|
EU/2/17/218 |
Bovilis Blue-8 |
Liechtenstein |
31.3.2024 |
|
EU/2/17/218 |
Bovilis Blue-8 |
Norway |
9.4.2024 |
|
EU/1/09/558 |
Clopidogrel BGR |
Norway |
23.1.2024 |
|
EU/1/12/784 |
Cuprymina |
Iceland |
21.2.2024 |
|
EU/1/12/784 |
Cuprymina |
Liechtenstein |
31.1.2024 |
|
EU/1/12/784 |
Cuprymina |
Norway |
12.3.2024 |
|
EU/1/22/1711 |
Dimethyl fumarate Accord |
Iceland |
9.1.2024 |
|
EU/1/22/1711 |
Dimethyl fumarate Accord |
Liechtenstein |
31.12.2023 (1) |
|
EU/1/22/1634 |
Dimethyl fumarate Mylan |
Iceland |
9.1.2024 |
|
EU/1/22/1634 |
Dimethyl fumarate Mylan |
Liechtenstein |
31.12.2023 (1) |
|
EU/1/22/1637 |
Dimethyl fumarate Neuraxpharm |
Iceland |
9.1.2024 |
|
EU/1/22/1637 |
Dimethyl fumarate Neuraxpharm |
Liechtenstein |
31.12.2023 (1) |
|
EU/1/22/1635 |
Dimethyl fumarate Polpharma |
Iceland |
9.1.2024 |
|
EU/1/22/1635 |
Dimethyl fumarate Polpharma |
Liechtenstein |
31.12.2023 (1) |
|
EU/1/22/1702 |
Dimethyl fumarate Teva |
Iceland |
9.1.2024 |
|
EU/1/22/1702 |
Dimethyl fumarate Teva |
Liechtenstein |
31.12.2023 (1) |
|
EU/2/20/268 |
Enteroporc Coli |
Iceland |
12.4.2024 |
|
EU/2/20/268 |
Enteroporc Coli |
Liechtenstein |
31.3.2024 |
|
EU/2/20/268 |
Enteroporc Coli |
Norway |
11.4.2024 |
|
EU/1/20/1520 |
Lenalidomide Krka d.d. Novo mesto |
Iceland |
11.1.2024 |
|
EU/1/20/1520 |
Lenalidomide Krka d.d. Novo mesto |
Liechtenstein |
30.9.2023 (1) |
|
EU/1/20/1520 |
Lenalidomide Krka d.d. Novo mesto |
Norway |
23.1.2024 |
|
EU/1/18/1290 |
Nityr |
Liechtenstein |
30.6.2024 |
|
EU/1/20/1499 |
Onbevzi |
Norway |
24.1.2024 |
|
EU/1/18/1283 |
Pemetrexed Krka |
Liechtenstein |
30.6.2024 |
|
EU/1/12/764 |
Pixuvri |
Iceland |
18.6.2024 |
|
EU/1/12/764 |
Pixuvri |
Liechtenstein |
30.9.2023 (1) |
|
EU/1/12/764 |
Pixuvri |
Norway |
12.6.2024 |
|
EU/1/96/018 |
Rapilysin |
Iceland |
21.2.2024 |
|
EU/1/96/018 |
Rapilysin |
Liechtenstein |
31.1.2024 |
|
EU/1/96/018 |
Rapilysin |
Norway |
8.2.2024 |
|
EU/1/99/110 |
Sustiva |
Iceland |
21.2.2024 |
|
EU/1/99/110 |
Sustiva |
Liechtenstein |
29.2.2024 |
|
EU/1/99/110 |
Sustiva |
Norway |
22.2.2024 |
|
EU/1/11/719 |
Telmisartan Teva Pharma |
Liechtenstein |
30.4.2024 |
|
EU/1/11/719 |
Telmisartan Teva Pharma |
Norway |
21.5.2024 |
|
EU/1/22/1639 |
Truvelog Mix 30 |
Iceland |
22.2.2024 |
|
EU/1/22/1639 |
Truvelog Mix 30 |
Liechtenstein |
31.1.2024 |
|
EU/1/22/1639 |
Truvelog Mix 30 |
Norway |
22.2.2024 |
|
EU/1/21/1529 |
Vaxzevria |
Iceland |
2.5.2024 |
|
EU/1/21/1529 |
Vaxzevria |
Liechtenstein |
31.3.2024 |
|
EU/1/21/1529 |
Vaxzevria |
Norway |
9.4.2024 |
|
EU/1/21/1580 |
VidPrevtyn Beta |
Iceland |
19.3.2024 |
|
EU/1/21/1580 |
VidPrevtyn Beta |
Liechtenstein |
31.3.2024 |
|
EU/1/21/1580 |
VidPrevtyn Beta |
Norway |
4.4.2024 |
|
EU/1/12/759 |
Zoledronic acid Actavis |
Iceland |
20.3.2024 |
|
EU/1/12/759 |
Zoledronic acid Actavis |
Liechtenstein |
31.3.2024 |
|
EU/1/12/759 |
Zoledronic acid Actavis |
Norway |
4.4.2024 |
|
EU/1/12/800 |
Zoledronic acid Hospira |
Iceland |
19.3.2024 |
|
EU/1/12/800 |
Zoledronic acid Hospira |
Liechtenstein |
29.2.2024 |
(1) Authorisation was unintentionally omitted from the list for the 2nd half of 2023.
ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 January – 30 June 2024:
|
EU-Number |
Product |
Country |
Date of suspension |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ELI: http://data.europa.eu/eli/C/2025/950/oj
ISSN 1977-091X (electronic edition)